-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The A-share trading in 2021 has come to an end, but there is still a batch of new stock subscriptions rushing for the last train
.
It was reported on December 27 that Asieris Pharmaceuticals opened the IPO subscription.
The company plans to issue 110 million shares (20.
9 million online and 85.
8 million offline) at an issue price of 22.
98 yuan per share, raising a total of 2.
528 billion yuan
.
Asieris is a company focusing on genitourinary tumors and other major diseases.
One of the issuer's core product candidates, APL-1202, is a First-in-Class oral inhibitor that has entered pivotal/phase III clinical trials against tumors.
, is also the first oral targeted therapy drug to enter pivotal/phase III clinical trials in the world, with huge market potential
.
At present, there are two indications of this product in China, which are advancing Phase III clinical trials, which are combined chemotherapy and infusion as second-line treatment for recurrent intermediate and high-risk non-muscle invasive bladder cancer (hereinafter referred to as: NMIBC); single-agent first-line treatment for untreated intermediate Endangered NMIBC
.
The prospectus shows that in 2020, the number of new bladder cancer patients worldwide will be 573,000, and it is expected to reach 651,000 in 2025; to 101,000 people
.
At present, the competitive environment of NMIBC is relatively loose.
In recent years, except for Merck's PD-1 tumor immunosuppressant pembrolizumab, which has been conditionally approved as a single drug for the treatment of specific high-risk NMIBC patients, no other new drugs in the NMIBC therapeutic area have been approved for marketing
.
Another key product is APL-1702 for the non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by all HPV subtypes
.
Asieris Pharmaceuticals responded to investors' questions on the online roadshow, saying that by the end of 2020, the penetration rate of HPV vaccine in the population suitable for APL-1702 is still less than 2%
.
With the increase in the number of people who are immune to HPV virus in China, the number of target patients with cervical precancerous lesions for the company's APL-1702 products will be affected to a certain extent
.
In China, only Fudan Zhangjiang and Dongfanglue Bio have related products under development
.
It is worth mentioning that, as of now, Asieris Pharmaceuticals has not yet achieved the listing of its products and has not been able to generate revenue.
The company plans to adopt the fifth set of listing standards for listing
.
Financial data shows that from 2019 to the first three quarters of 2021, Asieris Pharmaceuticals lost 172 million yuan, 247 million yuan, and 172 million yuan respectively
.
As of the first three quarters of 2021, Asieris has total assets of RMB 756 million and net assets of RMB 696 million
.
The company plans to raise 2.
528 billion yuan, of which 2.
070 billion yuan is planned to be invested in the production of medicines, medical devices and supporting creams (539 million yuan), new drug research and development (1.
206 billion yuan), and marketing network construction (130 million yuan) , Supplementary working capital (200 million yuan)
.
At present, the news of the subscription of Asieris Pharmaceuticals has attracted the attention of the industry
.
Some analysts pointed out that previously, like Asieris, the second new stock, Dizhe Pharmaceutical-U, which had products on the market in the future and did not realize revenue, was abandoned by 148,000 shares, and broke on the first day of listing.
It signed a loss of more than 5,000 yuan.
As of December 24, its share price fell nearly 38% from the issue price
.
In addition, this year, many new stocks on the Science and Technology Innovation Board have suffered losses from winning the lottery.
For example, BeiGene and Chengda Biology have a single-signal loss of more than 15,000 yuan, resulting in varying degrees of losses for investors; on the ChiNext, listing this year Hualan shares, Kefu Medical and other new stocks broke, and the winning investors also faced a lot of losses
.
Therefore, it is worth worrying whether Asieris will become the second Dizhe
.
However, for Asieris, Guotai Junan reminded that the genitourinary drug market in which the company is located has shown a rapid growth trend in recent years.
It is estimated that by 2030, the global and national genitourinary drug market will reach US$149.
9 billion and 198.
7 billion respectively
.
As of the end of June 2021, a number of innovative drugs for NMIBC and HSIL have been in clinical trials worldwide, and it is expected that the market competition in this field will increase in the future
.
.
It was reported on December 27 that Asieris Pharmaceuticals opened the IPO subscription.
The company plans to issue 110 million shares (20.
9 million online and 85.
8 million offline) at an issue price of 22.
98 yuan per share, raising a total of 2.
528 billion yuan
.
Asieris is a company focusing on genitourinary tumors and other major diseases.
One of the issuer's core product candidates, APL-1202, is a First-in-Class oral inhibitor that has entered pivotal/phase III clinical trials against tumors.
, is also the first oral targeted therapy drug to enter pivotal/phase III clinical trials in the world, with huge market potential
.
At present, there are two indications of this product in China, which are advancing Phase III clinical trials, which are combined chemotherapy and infusion as second-line treatment for recurrent intermediate and high-risk non-muscle invasive bladder cancer (hereinafter referred to as: NMIBC); single-agent first-line treatment for untreated intermediate Endangered NMIBC
.
The prospectus shows that in 2020, the number of new bladder cancer patients worldwide will be 573,000, and it is expected to reach 651,000 in 2025; to 101,000 people
.
At present, the competitive environment of NMIBC is relatively loose.
In recent years, except for Merck's PD-1 tumor immunosuppressant pembrolizumab, which has been conditionally approved as a single drug for the treatment of specific high-risk NMIBC patients, no other new drugs in the NMIBC therapeutic area have been approved for marketing
.
Another key product is APL-1702 for the non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by all HPV subtypes
.
Asieris Pharmaceuticals responded to investors' questions on the online roadshow, saying that by the end of 2020, the penetration rate of HPV vaccine in the population suitable for APL-1702 is still less than 2%
.
With the increase in the number of people who are immune to HPV virus in China, the number of target patients with cervical precancerous lesions for the company's APL-1702 products will be affected to a certain extent
.
In China, only Fudan Zhangjiang and Dongfanglue Bio have related products under development
.
It is worth mentioning that, as of now, Asieris Pharmaceuticals has not yet achieved the listing of its products and has not been able to generate revenue.
The company plans to adopt the fifth set of listing standards for listing
.
Financial data shows that from 2019 to the first three quarters of 2021, Asieris Pharmaceuticals lost 172 million yuan, 247 million yuan, and 172 million yuan respectively
.
As of the first three quarters of 2021, Asieris has total assets of RMB 756 million and net assets of RMB 696 million
.
The company plans to raise 2.
528 billion yuan, of which 2.
070 billion yuan is planned to be invested in the production of medicines, medical devices and supporting creams (539 million yuan), new drug research and development (1.
206 billion yuan), and marketing network construction (130 million yuan) , Supplementary working capital (200 million yuan)
.
At present, the news of the subscription of Asieris Pharmaceuticals has attracted the attention of the industry
.
Some analysts pointed out that previously, like Asieris, the second new stock, Dizhe Pharmaceutical-U, which had products on the market in the future and did not realize revenue, was abandoned by 148,000 shares, and broke on the first day of listing.
It signed a loss of more than 5,000 yuan.
As of December 24, its share price fell nearly 38% from the issue price
.
In addition, this year, many new stocks on the Science and Technology Innovation Board have suffered losses from winning the lottery.
For example, BeiGene and Chengda Biology have a single-signal loss of more than 15,000 yuan, resulting in varying degrees of losses for investors; on the ChiNext, listing this year Hualan shares, Kefu Medical and other new stocks broke, and the winning investors also faced a lot of losses
.
Therefore, it is worth worrying whether Asieris will become the second Dizhe
.
However, for Asieris, Guotai Junan reminded that the genitourinary drug market in which the company is located has shown a rapid growth trend in recent years.
It is estimated that by 2030, the global and national genitourinary drug market will reach US$149.
9 billion and 198.
7 billion respectively
.
As of the end of June 2021, a number of innovative drugs for NMIBC and HSIL have been in clinical trials worldwide, and it is expected that the market competition in this field will increase in the future
.
